Craneware (LON:CRW) Earns “Buy” Rating from UBS Group

Craneware (LON:CRW)‘s stock had its “buy” rating reissued by equities researchers at UBS Group in a note issued to investors on Wednesday, Marketbeat Ratings reports. They presently have a GBX 570 price objective on the stock. UBS Group’s target price suggests a potential downside of 57.30% from the company’s current price.

Other equities analysts have also recently issued reports about the stock. Shore Capital Group reaffirmed a “buy” rating and set a GBX 2,850 price target on shares of Craneware in a research note on Tuesday, January 20th. Berenberg Bank restated a “buy” rating and set a GBX 2,900 target price on shares of Craneware in a report on Tuesday, January 20th. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of GBX 2,297.75.

Craneware Stock Up 1.5%

Shares of Craneware stock opened at GBX 1,335 on Wednesday. The firm has a market cap of £474.05 million, a PE ratio of 24.18 and a beta of 0.28. The business’s 50 day simple moving average is GBX 1,560.64 and its 200 day simple moving average is GBX 1,945.37. The company has a debt-to-equity ratio of 7.93, a quick ratio of 1.00 and a current ratio of 0.76. Craneware has a 52-week low of GBX 1,290 and a 52-week high of GBX 2,644.

About Craneware

For over 25 years, The Craneware Group (AIM:CRW.L) has been a leader in healthcare financial and operational transformation, delivering cutting-edge technologies that drive measurable impact. Our Trisus® cloud ecosystem unifies data, revenue intelligence, margin intelligence, and advanced analytics, enabling healthcare organizations to optimize performance, improve financial sustainability, and drive strategic growth. As a trusted Microsoft partner, we provide future-ready solutions-including the Best in KLAS Trisus Chargemaster – that simplify the complexities of healthcare finance and operations.